Background/Aims: Zedoarondiol, a sesquiterpene lactone compound, showed an antiproliferative activity on vascular smooth muscle cells in our previous study. However, whether it has a beneficial effect on endothelial cells injury induced by oxidized low-density lipoprotein (ox-LDL) remains unclear. This study was designed to investigate the protective effect of zedoarondiol on ox-LDL-induced injury of endothelial cells and explored its underlying mechanism. Methods: The protective effect of zedoarondiol on ox-LDL-induced human umbilical vein endothelial cells (HUVECs) injury were evaluated by Cell Counting Kit-8 (CCK-8) assay and released lactic dehydrogenase (LDH) activity assay. Oxidative stress was determined by malonedialdehyde (MDA) content and superoxide dismutase (SOD) activity. The level of reactive oxygen species (ROS) was measured by dichlorodihydrofluorescin diacetate (DCFH-DA) staining. The culture supernatant was collected for enzyme linked immune-sorbent assays (ELISA) of interleukine-1β (IL-1β), tumor necrosis factor-α (TNF-α), and monocyte chemoattractant protein-1 (MCP-1). Immunofluorescence staining was used to observe NF-E2-related factor 2 (Nrf2) translocation. Western blotting was performed to determine the expression of IL-1β, TNF-α, MCP-1, Kelch-like ECH associated protein 1 (Keap1), heme oxygenase-1 (HO-1), NAD(P)H: quinone oxidoreductase-1 (NQO1), and Nrf2. Results: Zedoarondiol attenuated HUVECs injury, up-regulated SOD activity, suppressed formation of MDA and ROS, and secretion and protein expression of IL-1β, TNF-α, and MCP-1 in injured HUVECs induced by ox-LDL. Zedoarondiol induced nuclear Nrf2 translocation from cytoplasm into nucleus and up-regulated expression of HO-1, NQO1, and Nrf2 in nucleus. All-trans-retinoic acid (ATRA), an inhibitor of Nrf2, abolished zedoarondiol-mediated anti-
Introduction
Endothelial cell dysfunction plays a vital role in the initiation and development of atherosclerosis (AS) [1] , which can be induced by various risk factors, such as oxidized lowdensity lipoprotein (ox-LDL), hyperglycemia, and hypertension [2] . Ox-LDL is considered as a vital contributor to endothelial cell dysfunction [3] . Therefore, attenuating ox-LDL-induced endothelial cell injury is a promising strategy against AS.
Zedoarondiol (Fig. 1A) , a sesquiterpene lactone, is an active compound extracted from Zedoariae rhizoma (Curcuma zedaria Roscoe). It has been reported that zedoarondiol attenuated D-galactosamine-induced liver injury in mice [4, 5] and inhibited inflammation in lipopolysaccharide (LPS)-stimulated murine macrophages via suppressing nuclear factor-kappa B (NF-κB) pathway [6] . Our previous study has demonstrated that coating stents with Zedoariae rhizoma essential components, mainly including zedoarondiol, suppressed neointimal formation and showed a well-developed endothelium in a porcine coronary arterial balloon-injury model [7] , suggesting that essential components of Zedoariae rhizoma play a favorable role in regulating vascular smooth muscle cells (VSMCs) proliferation and protecting injured endothelial cells. Moreover, our previous study also showed that zedoarondiol inhibited platelet-derived growth factor-BB (PDGF-BB)-induced VSMCs proliferation via AMP-activated protein kinase pathway [8] . However, little is known about the role of zedoarondiol in protecting injured endothelial cells.
In response to ox-LDL stimulation, endothelial cells undergo a series of biological changes, involving reducing nitric oxide bioavailability, triggering oxidative stress, and initiating inflammation, collectively accelerating atherogenesis [9] [10] [11] . Nuclear factorerythroid 2-related factor 2 (Nrf2), a redox-sensitive transcription factor, plays an important role in regulating cellular oxidative stress and inflammation. In physiological conditions, Nrf2 locates in the cytoplasm adjacent to Kelch-like ECH-associated protein 1 (Keap1) that suppresses Nrf2 activity. In the presence of oxidative or electrophilic stress, Nrf2 is released from Keap1, translocates to the nucleus, which results in binding to antioxidant response elements (ARE) in the promoter region and subsequently promoting the transcription of antioxidant and detoxifying genes, including heme oxygenase-1 (HO-1), NAD(P)H: quinone oxidoreductase-1 (NQO1), glutathione-S-transferases (GSTs), glutathione peroxidase (GPx), and so forth [12] . Nrf2 activation protects endothelial cells from oxidative damage [13] and inflammatory reaction [14] , indicating Nrf2 as a novel therapeutic target for AS [15, 16] .
In the present study, we hypothesized that zedoarondiol attenuates endothelial cells injury induced by ox-LDL by inhibiting oxidative stress and inflammation via Nrf2 activation. To test this hypothesis, we investigated the effect of zedoarondiol on ox-LDL-induced human umbilical vein endothelial cells (HUVECs) injury and explored its underlying mechanisms focusing on Nrf2 pathway.
Materials and Methods

Materials
Zedoarondiol was kindly provided by the Dalian Institute of Chemical Physics, Chinese Academy of Sciences (Dalian, Liaoning, China). Ox-LDL (UBC-ox-LDL5) was purchased from Beijing Peking UnionBiology Co. Ltd (Beijing, China). According to manufacturer's instruction, ox-LDL was fully oxidized and its concentration was 1.05mg/mL. It was packaged in a solution containing PBS at pH 7.5 and 20μM EDTA. Alltrans-retinoic acid (ATRA) was purchased from Sigma-Aldrich (St. Louis, MO, USA). Zedoarondiol and ATRA were dissolved in dimethylsulfoxide (DMSO, final concentration < 0.1%).The Cell Counting Kit-8 (CCK-8) was purchased from Dojindo Laboratories (Kumamoto, Japan). Endothelial Cell Medium (ECM) was purchased from Sciencell (San Diego, CA, USA). Assay kits of lactate dehydrogenase (LDH), malonedialdehyde (MDA), superoxide dismutase (SOD) and reactive oxygen species (ROS) were obtained from Jiancheng Biotech (Nanjing, Jiangsu, China). ELISA kits for interleukine-1β (IL-1β), tumor necrosis factor-α (TNF-α), and monocyte chemoattractant protein-1 (MCP-1) were purchased from Jiancheng Biotech (Nanjing, Jiangsu, China). The enhanced chemiluminescence (ECL) kit was obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Antibodies against IL-1β (sc-7884), TNF-α (sc-52746), MCP-1 (sc-52877), Nrf2 (sc-722), histone H3 (sc-8654), and β-actin (sc-81178) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Antibodies against Keap1 (8047) and NQO1 (3187) were purchased from Cell Signaling Technology (Danvers, MA, USA). The antibody for HO-1 (ab13248) and LOX-1 (ab60178) were purchased from Abcam (Cambridge, MA, USA). Horseradish peroxidase (HRP)-conjugated goat anti-rabbit immunoglobulin G (IgG) and anti-mouse IgG were obtained from Epitomics (Burlingame, CA, USA). NE-PER Nuclear and Cytoplasmic Extraction kit was purchased from Thermo Fisher Scientific (Waltham, MA, USA). The mounting medium with DAPI was obtained from Vector Laboratories (Burlingame, CA, USA).
Cell culture and treatment
HUVECs were purchased from ScienCell (San Diego, CA, USA). Cells were cultured in ECM with 5% fetal bovine serum (FBS), 1% endothelial cell growth supplement (ECGS), and 1% penicillin/streptomycin solution in a humidified atmosphere with 5% CO 2 at 37°C. HUVECs at passage 4-6 were used in the experiments. Each experiment was performed on HUVECs from three different donors.
To exclude the possibility that the solvent of ox-LDL, zedoarondiol and ATRA affect the experimental results, the solvent controls were designed in the preliminary experiment. The results showed that the treatment with EDTA (2.9μM, the solvent of ox-LDL), DMSO (0.1%, the solvent of zedoarondiol and ATRA) or EDTA (2.9μM) +DMSO (0.1%) had no significant impact on HUVECs viability and MDA concentration as compared with the control (Fig. 1B-C) .
To evaluate the effect of zedoarondiol on ox-LDL-induced HUVECs injury, cells were designed to the following groups: (1) control group: HUVECs were cultured routinely for 24 h; (2) ox-LDL group: HUVECs were treated with ox-LDL (150 μg/mL) [17] for 24 h; (3) three zedoarondiol pretreatment groups: HUVECs were pretreated with zedoarondiol at 5, 10, or 20 μg/mL [8] for 2 h, respectively, and then treated with ox-LDL (150 μg/mL) for 24 h; (4) Zed group: HUVECs were treated with zedoarondiol (20 μg/mL) for 24 h.
To determine the role of Nrf2 in zedoarondiol-mediated protective effect on ox-LDL-induced HUVECs injury, cells were divided into the five groups: (1) control group; (2) Zed group; (3) ox-LDL group; (4) oxLDL+Zed group: HUVECs were pretreated with zedoarondiol (20 μg/mL) for 2 h and then treated with ox-LDL (150 μg/mL) for 24 h; (5) ox-LDL+Zed+ATRA group: HUVECs were pretreated with zedoarondiol (20 μg/mL) and ATRA (5 µmol/L) [18] for 2 h and then treated with ox-LDL (150 μg/mL) for 24 h. The treatment of the first three groups was same to the above.
Cell viability
Cell viability was evaluated using the CCK-8 assay kit. HUVECs were plated in 96-well plates at a density of 5 × 10 3 cells/well. After treatment, 10 μL CCK-8 was added to each well for 2 h at 37°C. Absorbance at 450 nm was measured using a microplate reader (Tecan Infinite f200 Pro, Tecan Group Ltd, Männedorf, Switzerland).
LDH activity
HUVECs were plated in 6-well plates at a density of 2 × 10 5 cells/well. LDH in the culture medium was evaluated using a LDH activity assay kit (Jiancheng Biotech, Nanjing, Jiangsu, China) according to the manufacturer's protocol. Briefly, the medium samples were incubated with NADH and pyruvate for 15 min at 37 ℃. The enzymatic reaction was stopped by adding 0.4 mol/L NaOH. Absorbance at 450 nm was measured by the microplate reader.
MDA level and SOD activity
Cells were seeded in T-25 flasks at a density of 5 × 10 5 cells/flask. After treatment, cells were collected and resuspended in lysis buffer. Protein concentration was determined using the bicin-choninic acid (BCA) method. The MDA level was measured by the thiobarbituric acid (TBA) method using a lipid peroxidation Cellular Physiology and Biochemistry
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MDA assay kit (Jiancheng Biotech, Nanjing, Jiangsu, China) according to the manufacturer's instructions. Absorbance at 530 nm was measured by the microplate reader. SOD activity was evaluated by the xanthine oxidase method using a SOD activity assay kit (Jiancheng Biotech, Nanjing, Jiangsu, China) according to the manufacturer's instructions. Absorbance was measured at 450 nm by the microplate reader.
ROS production ROS production was determined using a ROS assay kit (Beyotime Biotech, Shanghai, China) according to the manufacturer's protocol. Cells were seeded in 6-well plates at a density of 2 × 10 5 cells/well. After treatment, cells were harvested, washed twice with PBS, and incubated with serum-free media containing 10 μmol/L DCFH-DA at 37 ℃ for 30 min in the dark. Subsequently, cells were washed twice with serum-free medium. The ROS level was detected using a FACSCalibur flow cytometer (BD Biosciences, Franklin Lakes, NJ, USA).
Levels of IL-1β, TNF-α, and MCP-1
The levels of IL-1β, TNF-α, and MCP-1 in the culture medium were determined by ELISA (Jiancheng Biotech, Nanjing, Jiangsu, China) according to the manufacturer's instructions. Briefly, 50 µL standard solution or culture medium was added to each well, followed by incubation with a HRP-conjugated secondary antibody (50 µL/well) for 2 h at 37 ℃. Cells were washed three times with washing buffer and incubated with 100 µL/well substrate solution for 10 min at 37 ℃. 50 µL of sulfuric acid (1 M) was added to stop the enzymatic reaction and the absorbance was measured at 450 nm by the microplate reader.
Nrf2 nuclear translocation
Nrf2 nuclear translocation was observed by immunofluorescence staining. HUVECs grown on coverslips were fixed in 4 % paraformaldehyde for 15 min at 4℃ and blocked with 10 % donkey serum containing 1 % BSA and 0.2 % Triton X-100 for 50 min at room temperature. Next, cells were incubated with anti-Nrf2 rabbit polyclonal antibody (1:50 diluted) overnight at 4 ℃ and then probed with Texas red-conjugated donkey anti-rabbit secondary antibody (1:100) for 2 h at room temperature in the dark. DAPI was added for nuclear staining. The cells were observed under a confocal scanning microscope (630× amplification; Zeiss LSM-510 Meta, Jena, Germany). For the quantitative analysis, mean fluorescence intensity per cell was calculated from 3 random fields of each group with Image-Pro Plus software (Roper Industries, New York, NY, USA).
Western blot analysis
Cells were collected and lysed in lysis buffer containing HEPES (20.0 mM), β-glycerophosphate (20 mM), Na3VO4 (0.1 mM), MgCl2 (2.5 mM), NaCl (5 mM), DTT (0.5 mM), EDTA (0.1 mM), leupeptin 4 (μg/mL), PMSF 20 (μg/mL), and Triton X-100 (0.05% v/v). The protein concentration was measured by BCA method. The equivalent amounts of protein (80 μg/lane) was separated by 8-12% sodium dodecyl sulfate-polyacrylamide gels for electrophoresis and then electrophoretically transferred to nitrocellulose membranes. After blocked with 5% bovine serum albumin (BSA) in Tris-buffered saline containing 0.1% Tween 20 (TBS-T) for 2 h at room temperature, the membranes were incubated with primary antibodies at 4 °C overnight. The membranes were incubated with corresponding HRP-conjugated secondary antibodies for 2 h. Protein bands were visualized using an ECL kit. Image-Pro Plus software was applied to quantify the optical density of bands. Protein expression was normalized to β-actin. In addition, Nrf2 protein in the cytoplasm and nucleus were obtained by using NE-PER nuclear and cytoplasmic extraction reagents. Histone H3 was used as an internal control for nuclear Nrf2 protein.
Statistical analyses SPSS 17.0 software (IBM, Chicago, IL, USA) was applied for statistical analyses. Data were presented as mean ± standard deviation (SD). Differences were evaluated by one-way analysis of variance (ANOVA) followed by Tukey's post-hoc test. A value of P < 0.05 was considered statistically significant.
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Results
Zedoarondiol increases viability and inhibits released LDH activity in injured HUVECs induced by ox-LDL
In the present study, we first evaluated the protective effect of zedoarondiol on ox-LDL-induced HUVECs injury by CCK-8 assay.
Ox-LDL (150 µg/mL) significantly decreased HUVECs viability by 58% (P<0.05 vs. control). As compared with the ox-LDL group, zedoarondiol pretreatment at 5, 10, and 20 µg/mL followed by ox-LDL (150 µg/mL) treatment alleviated the decreased viability by 77%, 102%, and 134%, respectively (P<0.05 vs. ox-LDL; Fig. 2A ). However, zedoarondiol (20 µg/mL) treatment did not affect the viability of HUVECs in the control group (P>0.05 vs. control; Fig. 2A) .
We examined the effect of zedoarondiol on ox-LDL-induced HUVECs injury by the released LDH activity assay. Ox-LDL (150 µg/mL) led to an increase in released LDH activity by 67% (P<0.05 vs. control); pretreatment with zedoarondiol at 5, 10, and 20 µg/mL followed by ox-LDL (150 µg/mL) treatment attenuated LDH activity by 34%, 35%, and 38%, respectively (P<0.05 vs. ox-LDL; Fig. 2B ). No significant difference was observed between the control group and Zed group (P>0.05; Fig. 2B ).
Zedoarondiol reduces ox-LDL-induced oxidative stress in HUVECs
MDA is formed during lipid peroxidation caused by free radicals. SOD is a major endogenous antioxidant enzyme which protects endothelial cells against oxidative damage. Thus, we evaluated the effect of zedoarondiol on MDA level and SOD activity in injured HUVECs induced by ox-LDL. Ox-LDL markedly increased MDA level (P<0.05 vs. control) and decreased SOD activity (P<0.05 vs. control). When compared with ox-LDL group, pretreatment with zedoarondiol at 5, 10, and 20 µg/mL decreased MDA level by 21%, 31%, and 37%, respectively (P<0.05; Fig. 2C) ; zedoarondiol pretreatment at 10 and 20 µg/mL alleviated the decreased SOD activity by 36% and 49%, respectively (P<0.05 vs. ox-LDL; Fig.  2D ). Zedoarondiol (20 µg/mL) treatment did not affect the MDA level and SOD activity of HUVECs in the control group (P>0.05 vs. control).
Taken together, zedoarondiol at 20 µg/mL showed a pronounced protective effect on ox-LDL-induced HUEVCs injury. Therefore, zedoarondiol at 20 µg/mL was used in the subsequent experiments.
LOX-1, known as the major scavenger receptor for ox-LDL uptake in endothelial cells, plays a pivotal role in atherogenic process [19] . Thus, we first evaluated the effect of zedoarondiol on LOX-1 expression. Ox-LDL (150 µg/mL) led to a 124% increase in LOX-1 expression (P<0.05 vs. control). Zedoarondiol (20 µg/mL) pretreatment followed by ox-LDL down-regulated LOX-1 expression by 53% (P<0.05 vs. ox-LDL; Fig. 2E ).
Increased ROS are a major cause of oxidative stress. We investigated the effect of zedoarondiol on intracellular ROS level by flow cytometry. As compared with the control group, ox-LDL treatment resulted in a 3.4-fold increase in ROS level (P<0.05 vs. control); pretreatment with zedoarondiol at 20 μg/mL decreased ROS level by 57% (P<0.05 vs. ox-LDL; Fig. 2F ), indicating that the protective effect of zedoarondiol on ox-LDL-induced HUEVCs injury may be associated with reduced oxidative stress. 
Zedoarondiol attenuates o x -L D L -i n d u c e d inflammation in HUVECs
To investigate the effect of zedoarondiol on inflammatory reaction in injured HUVECs induced by ox-LDL, levels of IL-1β, MCP-1, and TNF-α in the culture medium were determined by ELISA. As compared with the control group, the levels of IL-1β, MCP-1, and TNF-α were significantly increased in the ox-LDL group (P<0.05); zedoarondiol (20 μg/mL) pretreatment followed by ox-LDL (150 μg/mL) treatment reduced levels of IL-1β, MCP-1, and TNF-α by 56%, 67%, and 42%, respectively (P<0.05 vs. ox-LDL; Fig. 3A-C) . There was no significant difference between the control group and Zed group (P>0.05 vs. control).
To further evaluate the inhibitory effect of zedoarondiol in ox-LDLinduced inflammation, the protein expression of IL-1β, MCP-1, and TNF-α were detected with western blotting. Ox-LDL treatment obviously increased protein expression of IL-1β, MCP-1, and TNF-α (P<0.05 vs. control). In comparison with ox-LDL group, pretreatment with zedoarondiol (20 μg/ mL) led to a 14%, 51%, and 26% reduction in protein expression of IL-1β, MCP-1, and TNF-α, respectively (P<0.05 vs. ox-LDL; Fig.  3D-G) , indicating that the cytoprotection effect of zedoarondiol was partly mediated by its anti-inflammatory activity.
Nrf2 activation is associated with protective effect of zedoarondiol-mediated on ox-LDLinduced HUVECs injury
To determine whether the protective effect of zedoarondiol on ox-LDL-induced HUVECs injury was mediated by Nrf2 activation, cells were co-treated with ATRA, an Nrf2 inhibitor. As compared with ox-LDL+Zed group, pretreatment with zedoarondiol and ATRA resulted in a 36% increase in MDA level and a 14% decrease in SOD activity (P<0.05; Fig. 4A-B) , Nrf2 distributed predominantly in the cytoplasm in the control group. As compared with ox-LDL group, the mean fluorescence intensity of nuclear Nrf2 in ox-LDL+Zed group was increased by 57% (P<0.05; Fig. 4C ), suggesting that zedoarondiol induced Nrf2 nuclear translocation in the background of ox-LDL treatment.
To illustrate the role of Nrf2 in zedoarondiol-mediated protective effect on injured HUVECs induced by ox-LDL, Nrf2 protein expression in the cytoplasm and nucleus was detected with western blotting. As compared with ox-LDL group, zedoarondiol (20 μg/ mL) pretreatment followed by ox-LDL (150 μg/mL) resulted in a 19% decrease (P<0.05 vs. ox-LDL; Fig. 5A ) in cytoplasmic Nrf2 protein and a 39% increase (P<0.05 vs. ox-LDL; Fig. 5B ) in nuclear Nrf2. In addition, considering the vital role of Keap1 in Nrf2 translocation, Keap1 expression was detected. As compared with ox-LDL group, zedoarondiol pretreatment significantly inhibited Keap1 expression (P<0.05 vs. ox-LDL; Fig.  5C ), indicating that zedoarondiol induced Nrf2 translocation probably through suppressing Keap1 expression.
HO-1 and NQO1 are the crucial downstream of Nrf2, which are involved in Nrf2-mediated protective effect on injured endothelial cells [20, 21] . Therefore, we detected expression of HO-1 and NQO1 with western blotting. In comparison with the control group, ox-LDL treatment increased HO-1 and NQO1 expression by 275% and 98%, respectively (P<0.05). Pretreatment with zedoarondiol further increased expression of HO-1 and NQO1 by 12% and 28%, respectively, as compared with ox-LDL treatment alone (P<0.05; Fig. 5D-E) . Cell
Discussion
In this study, we investigated the effect of zedoarondiol on ox-LDL-induced HUVECs injury and explored its possible mechanism. Our findings demonstrated that: (1) zedoarondiol attenuated ox-LDL-induced endothelial cells injury, while it has no impact on the routine cultured endothelial cells; (2) the protective effect of zedoarondiol was associated with inhibition of oxidative stress and inflammation via Nrf2 pathway.
Endothelial cells dysfunction is well-known as a critical event in the AS pathogenesis [22] . Given the critical role of ox-LDL in endothelial cell dysfunction and subsequent AS [23] , we used the model of ox-LDL-induced HUVECs injury to investigate the protective effect of zedoarondiol. Zedoarondiol is a sesquiterpene lactone extracted from Zedoariae rhizome. The present study demonstrated that zedoarondiol alleviated ox-LDL-induced HUVECs injury, as evidenced by alleviated decreased cell viability and inhibited released LDH activity in the culture medium. Our previous study showed that zedoarondiol inhibited PDGF-BBinduced VSMCs proliferation via AMP-activated protein kinase pathway [8] . Because that endothelial cells, macrophages and VSMCs collectively modulate the development of AS [24] , zedoarondiol is supposed to be meaningful on prevention and treatment of AS.
Oxidative stress is closely associated with endothelial cell injury and AS pathogenesis [25] . Oxidative stress induced by ox-LDL mainly results from excessive ROS generation and decreased activity of anti-oxidative enzymes, such as SOD [26] . This study revealed that ox-LDL elevated the level of MDA, a lipid peroxidation marker, increased ROS generation, and decreased SOD activity. Zedoarondiol pretreatment markedly attenuated ox-LDL-induced oxidative stress, as evidenced by increased SOD activity and decreased levels of MDA and ROS, indicating that zedoarondiol-mediated protective effect on ox-LDL-induced HUVECs injury is related to inhibiting oxidative stress. Notably, in the present study, the level of intracellular ROS was determined by a flow cytometer using DCFH-DA fluorescent probe, which has been recognized as a classic method to determine ROS generation. However, DCFH-DA is not ROSspecific, which can be also oxidized by nitric oxide and other low-molecular weight oxidants. Therefore, the ROS level may be underestimated.
Inflammation participates in AS formation from onset of AS plaque to plaque rupture [27, 28] . Inflammatory cytokines, such as IL-1β and TNF-α, up-regulate endothelial adhesion molecules and promote the recruitment of monocytes into the sub-endothelium [29] . MCP-1, a potent monocyte attractant, also contributes to monocyte recruitment [30] . Recently, anti-inflammatory therapies have been proposed as possible adjuncts to the current treatment for AS [31] . Zedoarondiol has been reported to have an anti-inflammatory effect on LPS-stimulated murine macrophage [6] . The finding in the present study showed that zedoarondiol significantly decreased both secretion and protein expression of IL-1β, TNF-α, and MCP-1 in injured HUVECs induced by ox-LDL, indicating that zedoarondiol attenuates ox-LDL-induced inflammation in HUVECs.
Nrf2, a redox-sensitive transcription factor, is closely associated with AS pathogenesis [32] . Nrf2 -/-LDL receptor knockout (LDLR KO) mice exhibited accelerated atherosclerotic lesions as compared with Nrf2 +/+ LDLR KO mice [33] . Increasing studies in vitro have demonstrated that Nrf2 activation is associated with inhibiting oxidative stress as well as inflammation. In endothelial cells, Nrf2 activation is accompanied with decreased ROS generation [34] . Additionally, elevated Nrf2 activity suppresses TNF-α-induced MCP-1 secretion, VCAM-1 expression, and NF-κB pathway [35] . Several natural products, such as curcumin [36] , salvianolic acid A [37] , and miltirone [38] , acting as Nrf2 activators, have been shown to retard AS progression. In the present study, we found that zedoarondiol activated Nrf2 in ox-LDL-treated HUVECs, as evidenced by Nrf2 translocation into the nucleus and upregulation of Nrf2 expression in the nucleus. In addition, the protective effect of zedoarondiol was abolished by ATRA, an Nrf2 inhibitor, suggesting that Nrf2 activation plays a role in the protective effect of zedoarondiol on ox-LDL-induced HUVECs injury.
In physiological conditions, Nrf2 binds to Keap1, locating in the cytoplasm. Oxidative or electrophilic stress enables Nrf2 to release from Keap1 and translocate to the nucleus.
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Thereafter, Nrf2 binds to ARE and induces the transcription of antioxidant and detoxifying genes, among which, HO-1 and NQO1 play crucial roles in anti-atherosclerosis due to their anti-oxidative and anti-inflammatory activities [39, 40] . In this study, zedoarondiol up-regulated expression of HO-1 and NQO1 in injured HUVECs induced by ox-LDL, suggesting that HO-1 and NQO1 are associated with the protective effect of zedoarondiol in ox-LDL-induced endothelial cells injury.
In addition, an interesting finding in the present study was that although zedoarondiol showed many favorable effects in ox-LDL-induced endothelial cells injury, it did not have impact on the cells without ox-LDL stimulation, which is meaningful in preventing and treating AS.
Although the present study indicates the protective effect of zedoarondiol on the ox-LDL-induced injury of endothelial cells, several limitations should be noted. First, we used ATRA to inhibit Nrf2 activation in the present study, and the results showed that additional ATRA to zedoarondiol pretreatment abolished zedoarondiol-mediated anti-oxidative effect on injured HUVECs. Considering ATRA is an exogenous and non-specific inhibitor of Nrf2, if Nrf2 -/-knocked-out cells, or cells genetically knocked down with siRNA were employed in the present studies, whether the cellular protective effect of zedoarondiol is associated with Nrf2 would be identified more clearly. Second, Nrf2 activation has been evidenced by increased Nrf2 translocation and nuclear Nrf2 expression in the present study. If phosphorylation status of Nrf2 at serine 40 has been examined, the determination of Nrf2 activation would be more credible. Third, intracellular ROS formation was found to be increased with ox-LDL treatment in the present study. However, it did not show the potential sources of intracellular ROS, which needs to be studied in future. Lastly, although the solvent controls were designed in the preliminary experiment and the results showed no significant impact of solvent treatment on HUVECs viability and MDA concentration, the comparison of experimental results between groups would be more reasonable, if the solvent controls were applied in all experiments.
In conclusion, our study demonstrated that zedoarondiol, a sesquiterpene lactone compound extracted from Zedoariae rhizoma, attenuated endothelial cells injury induced by ox-LDL. The underlying mechanism was associated with inhibition of oxidative stress and inflammation via Nrf2 pathway (Fig. 6 ). These findings suggest that zedoarondiol might be meaningful on prevention and treatment of AS.
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